Additionally, targeting CS-GRP78 also regulated the activity of β-site APP-cleaving enzyme 2 (BACE2) via lysosomal degradation, this resulted in reduced tumour growth and resistance to radiation in the MES GSCs [87]. Here, CS is linked to neoplasm.